We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GIS:NYSEGeneral Mills, Inc. Analysis

Data as of 2026-08-30 - not real-time

$41.55

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

General Mills, Inc. is priced at $41.55, and its moving averages give no clean directional read — the structure is neutral. It has gained 9.4% over the past 30 days. Momentum indicators put RSI at 67.2 (approaching overbought) with MACD reading bullish. Watch $35.39 as support and $41.67 as the nearer resistance level.
On valuation the read is overvalued — an earnings multiple of 12.9, absent a reliable peer benchmark. Analyst price targets sit 9.6% below the current price. Revenue is growing at 2.2% on a -0.5% profit margin. The 6.03% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 32.3%, a beta of -0.29 and a maximum drawdown of 37.1%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons diverge: hold near-term but sell on a long view, at 4/10 conviction over the longer horizon.

Top Market Events

The Kraft Heinz Company NASDAQ:KHC and General Mills, Inc.General Mills stock has had a weak run over the past few years, while current valuation checks suggest the shares are...General Mills NYSE: GIS has put forward a proposal to amend its bylaws to address officer exculpation and a federal...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading above the 200-day average of 40.08
  • MACD momentum is positive
  • 30-day price change of +9.4%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 40.08
  • Analyst targets imply -9.6% versus the current price
  • MACD momentum is positive

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Negative profit margin of -0.5%
  • Analyst targets imply -9.6% versus the current price
  • Negative return on equity of -1.0%

Key Metrics & Analysis

Financial Health

Revenue Growth2.20%
Profit Margin-0.47%
P/E Ratio12.9
ROE-1.03%
ROA5.74%
Debt/Equity217.63
P/B Ratio4.0
Op. Cash Flow$2.2B
Free Cash Flow$2.3B

Technical Analysis

TrendNeutral
RSI67.2
Support$35.39
Resistance$41.67
MA 20$38.55
MA 50$37.22
MA 200$40.08
MACDBullish
VolumeStable
Fear & Greed Index95.66

Valuation

Fair Value$61.69
Target Price$37.56
Upside/Downside-9.61%
GradeOvervalued
TypeValue
Dividend Yield6.03%

Risk Assessment

Beta-0.29
Volatility32.27%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.